Erlocip Erlotinib 150 mg Tablets
3520 INR/Bottle
Product Details:
- Salt Composition Erlotinib Hydrochloride 150 mg
- Indication Non-Small Cell Lung Cancer, Pancreatic Cancer
- Dosage Form Tablet
- Enzyme Types Erlocip Erlotinib 150 mg Tablets
- Feature Oral anticancer medication
- Ingredients Erlotinib Hydrochloride and excipients
- Application Other
- Click to View more
X
Erlocip Erlotinib 150 mg Tablets Price And Quantity
- 3520 INR/Bottle
- 1 Bottle
Erlocip Erlotinib 150 mg Tablets Product Specifications
- Dry Place
- Other
- Erlotinib Hydrochloride 150 mg
- White to off-white, round film-coated tablets
- Odorless
- Non-Small Cell Lung Cancer, Pancreatic Cancer
- Tablet
- Erlocip Erlotinib 150 mg Tablets
- Erlotinib Hydrochloride and excipients
- Oral anticancer medication
- 1 Years
Erlocip Erlotinib 150 mg Tablets Trade Information
- Cash Advance (CA)
- 7 Days
- All India
Product Description
Technical Specification
- Minimum Order Quantity : 1 Bottle
- Form : Tablet
- Packaging Size : 30
- Prescription/Non prescription : Prescription
- Treatment : Anti Cancer Medicines
- Manufacturer : Cipla
- Composition : erlotinib
- Brand : erlocip
Advanced Targeted Therapy for Cancer
Erlocip Erlotinib 150 mg Tablets offer targeted therapy for patients with non-small cell lung cancer and pancreatic cancer. By inhibiting specific enzymes crucial for cancer cell proliferation, this medication helps slow or halt disease progression. The oral administration simplifies treatment regimens, eliminating the need for intravenous infusions. With Cipla's mark of quality, Erlocip delivers reliable efficacy with a well-defined safety profile under medical supervision.
Proper Usage and Storage Recommendations
Erlocip tablets are intended for oral use as prescribed by your physician. Ensure they are stored in a dry place and kept away from moisture and direct sunlight. The product must be kept out of reach of children for safety. Adhering to the prescribed dosage and following your doctor's advice is essential to maximize therapeutic benefits and minimize risks. Always use this medication under strict medical guidance to ensure safety and efficacy.
FAQ's of Erlocip Erlotinib 150 mg Tablets:
Q: How should Erlocip Erlotinib 150 mg Tablets be taken?
A: Erlocip Erlotinib 150 mg Tablets must be taken orally, exactly as directed by your physician. It is typically recommended to take the tablet at least one hour before or two hours after eating for optimal absorption.Q: What cancers are indicated for treatment with Erlocip Erlotinib 150 mg Tablets?
A: Erlocip Erlotinib 150 mg Tablets are indicated for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer as prescribed by a qualified healthcare provider.Q: When should this medication be avoided or used with caution?
A: Do not use Erlocip without a prescription. It should be used with caution if you have liver or kidney issues, or if you are taking interacting medications. Consult your doctor about all medications and health conditions before starting therapy.Q: Where should Erlocip Erlotinib 150 mg Tablets be stored?
A: Store these tablets in a dry place, away from moisture and direct heat. Always keep them out of reach of children to prevent accidental ingestion.Q: What is the process for getting Erlocip Erlotinib 150 mg Tablets?
A: This medication requires a valid prescription from a licensed medical practitioner. Once prescribed, it can be obtained from authorized pharmacies, dealers, or distributors.Q: What are the benefits of using Erlocip Erlotinib 150 mg Tablets?
A: Erlocip offers targeted inhibition of cancer cell growth, potentially slowing disease progression in NSCLC and pancreatic cancer. Its oral form provides convenience compared to intravenous therapies.Tell us about your requirement
Price:
Quantity
Select Unit
- 50
- 100
- 200
- 250
- 500
- 1000+
Additional detail
Mobile number
Email
Other Products in 'Anti Cancer Medicine' category
DEV MEDICAL
All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Private Limited.
Developed and Managed by Infocom Network Private Limited.
